Table S4.

DHA, DPAn-3 and EPA bioactive metabolome identified in gut from I/R mice+EPA+scrambled control siRNA (mock) or I/R+EPA+ELOVL2 siRNA

Bioactive metabolomeQ1Q3I/R +EPA+scrambledI\R +EPA+ELOV2 siRNA
DHA bioactive metabolome
 RvD13751412.2 ± 1.335.6 ± 17.1*
 RvD23752153.3 ± 156.9 ± 28.2*
 RvD33751470.2 ± 0.14.3 ± 2.5
 RvD43752552.9 ± 1.6274.5 ± 167.6
 RvD53591993.8 ± 1.90.8 ± 0.1
 RvD63591591.5 ± 0.21.7 ± 0.5
 MaR13592500.2 ± 0.10.1 ± 0.0
 7S,14S-diHDHA3592501.4 ± 0.30.7 ± 0.0*
 4S,14S-diHDHA3592501.1 ± 0.52.9 ± 0.9*
 MaR23592501.1 ± 0.42.9 ± 1*
 PD13591530.5 ± 0.20.1 ± 0*
 10S,17S-diHDHA35915321.3 ± 10.53.6 ± 0.3*
 DHA3272833479.0 ± 736.44760.0 ± 697.4
n-3 DPA bioactive metabolome
 RvD1n-3 DPA3771430.5 ± 0.112.1 ± 6.8*
 RvD2n-3 DPA3772150.2 ± 0.08.8 ± 4.3*
 RvD5n-3 DPA3611990.1 ± 0.00.4 ± 0.1*
 MaR1n-3 DPA3612210.6 ± 0.31.6 ± 0.4*
 MaR2n-3 DPA3612210.9 ± 0.30.5 ± 0.0
 PD1n-3 DPA3611830.1 ± 0.00.3 ± 0.1*
 DPA329285709.5 ± 86.01095.0 ± 131.1*
EPA bioactive metabolome
 RvE13491610.1 ± 0.16.3 ± 1.7*
 RvE23332531.5 ± 0.91.2 ± 0.6
 RvE33332010.3 ± 0.20.7 ± 0.3
 EPA3292573479.0 ± 736.44760.7 ± 697.4
  • C57bl6 mice were transfected with either 40 μg mock or ELOVL2 siRNA (three injections every other day for 6 d) and given EPA (10 μg/d, i.p., every other day for 6 d) or vehicle (PBS 0.01% EtOH). At day 7 mice were subjected to 50-min intestinal ischemia followed by a 5-h reperfusion. Intestines were harvested and n-3 DPA, DHA, and EPA SPM were profiled using LM metabololipidomics. LM were profiled using LC-MS/MS–based techniques (Materials and Methods). Q1, M-H (parent ion) and Q3, diagnostic ion in the MS/MS (daughter ion). Results are expressed as pg/10-mg tissue; mean ± SEM, n = 4–5 mice per experimental group. *P < 0.05 vs. I/R+EPA+Scrambled group, Student's t test.